# An Open-label Extension Safety and Efficacy Study of QCZ484 in Hypertensive Patients.

Study · id `cardio:ct-nct07543120` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07543120](<https://clinicaltrials.gov/study/NCT07543120>), retrieved 18 November 2026. No person wrote or checked this page.

Also called: NCT07543120

Browse, organ or system: Blood vessels  
Browse, condition area: High blood pressure  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 323 participants.

## Technical summary

Registry record NCT07543120. Allocation not applicable; no masking; primary purpose treatment. Start 2026-05-07 (actual); primary completion 2031-05-07 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 323 participants (planned count; ClinicalTrials.gov record NCT07543120, source copy `cardio:ctgov-nct07543120-2026-11-16`, retrieved 2026-11-18)
- Started: 2026-05-07 (actual) (ClinicalTrials.gov record NCT07543120, source copy `cardio:ctgov-nct07543120-2026-11-16`, retrieved 2026-11-18)
- Primary completion: 2031-05-07 (anticipated) (ClinicalTrials.gov record NCT07543120, source copy `cardio:ctgov-nct07543120-2026-11-16`, retrieved 2026-11-18)
- Completion: 2031-11-07 (anticipated) (ClinicalTrials.gov record NCT07543120, source copy `cardio:ctgov-nct07543120-2026-11-16`, retrieved 2026-11-18)
- Countries: United States; Japan; Singapore (ClinicalTrials.gov record NCT07543120, source copy `cardio:ctgov-nct07543120-2026-11-16`, retrieved 2026-11-18)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07543120-2026-11-16`, retrieved 2026-11-18)

## The registry's words

- Brief title: An Open-label Extension Safety and Efficacy Study of QCZ484 in Hypertensive Patients.
- Condition: Hypertension (HTN)
- Intervention (Drug): QCZ484
- Lead sponsor: Novartis Pharmaceuticals
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)
- Registry lists this organization as the lead sponsor: Novartis (`cardio:novartis`)

## Provenance

Content hash: 5801eef701a0ac4edb21550bc0874b03115afc160158bbcb295585f6bc2fabc2
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
